share_log

Recursion Pharmaceuticals | 8-K: Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results

SEC announcement ·  Feb 27 22:39
Summary by Moomoo AI
On February 27, 2024, Recursion Pharmaceuticals, Inc., a clinical stage TechBio company, announced its financial results for the fourth quarter and fiscal year ended December 31, 2023. The announcement was made through a press release and included updates on the company's business operations and pipeline progress. Recursion reported a net loss of $93.0 million for the fourth quarter and $328.1 million for the fiscal year. Despite the losses, the company highlighted several key developments, including the progress of multiple clinical programs expected to provide Phase 2 data in the second half of 2024 and the first half of 2025, and the in-licensing of a novel program for treating fibrotic diseases. Recursion also emphasized its integration of causal AI models into its operating system, following a data partnership...Show More
On February 27, 2024, Recursion Pharmaceuticals, Inc., a clinical stage TechBio company, announced its financial results for the fourth quarter and fiscal year ended December 31, 2023. The announcement was made through a press release and included updates on the company's business operations and pipeline progress. Recursion reported a net loss of $93.0 million for the fourth quarter and $328.1 million for the fiscal year. Despite the losses, the company highlighted several key developments, including the progress of multiple clinical programs expected to provide Phase 2 data in the second half of 2024 and the first half of 2025, and the in-licensing of a novel program for treating fibrotic diseases. Recursion also emphasized its integration of causal AI models into its operating system, following a data partnership with Tempus. The company's cash and cash equivalents stood at $391.6 million as of December 31, 2023. Additionally, Recursion announced an updated investor presentation and a presentation made in connection with its L(earnings) call, both of which were released on the same day as the financial results. The company uses various channels, including SEC filings, its investor relations website, press releases, public conference calls, webcasts, and social media, to communicate with investors and the public.

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more